Silexion Therapeutics (SLXN) Cash & Equivalents (2023 - 2026)

Silexion Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 60.78% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 60.78% YoY), while the FY2025 annual figure was $27000.0, down 97.73% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.4 million, up from $27000.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $9.2 million in Q3 2025, with the low at $27000.0 in Q4 2025.
• The 4-year median for Cash & Equivalents is $3.1 million (2024), against an average of $3.8 million.
• Peak annual rise in Cash & Equivalents reached 368.47% in 2025, while the deepest fall reached 97.73% in 2025.
• Silexion Therapeutics' Cash & Equivalents stood at $4.6 million in 2023, then plunged by 74.17% to $1.2 million in 2024, then plunged by 97.73% to $27000.0 in 2025, then soared by 8837.04% to $2.4 million in 2026.
• Business Quant data shows SLXN's Cash & Equivalents at $2.4 million in Q1 2026, $27000.0 in Q4 2025, and $9.2 million in Q3 2025.